

25

- ④ For more records, click the Records link at page end.
- ⑤ To change the format of selected records, select format and click Display Selected.
- ⑥ To print/save clean copies of selected records from browser click Print/Save Selected.
- ⑦ To have records sent as hardcopy or via email, click Send Results.

 Select All Clear Selections

Print/Save Selected

Send Results

Format

Display Selected

Free

1. 11/5/1 DIALOG(R)File 352:Derwent WPI (c) 2006 The Thomson Corporation. All rts. reserv.

0008462569 Drawing available

WPI Acc no: 1997-402201/199737

Related WPI Acc No: 1996-116963

XRAM Acc no: C1997-129682

New sulphonylaryl-imidazole derivatives which are cyclooxygenase-2 selective inhibitors - headache, without causing side effects e.g. ulcers

Patent Assignee: SEARLE & CO G D (SEAR); COLLINS P W (COLL-I); HUFF R M (HUFF-I)
I; WEIER R M (WEIE-I); XU X (XUXX-I); YU Y (YUYY-I)Inventor: COLLINS P; COLLINS P W; HUFF R; HUFF R M; KHANNA I K; KOSZYK F; KOSZ
WEIR R ; XU X; YU U; YU Y

Patent Family (17 patents, 75 countries)

Patent Number	Kind	Date	Application Number	Kind	Date	Update	Type
WO 1997027181	A1	19970731	WO 1997US300	A	19970124	199737	B
AU 199715739	A	19970820	AU 199715739	A	19970124	199749	E
ZA 199700670	A	19980624	ZA 1997670	A	19970127	199831	E
EP 880504	A1	19981202	EP 1997901952	A	19970124	199901	E
			WO 1997US300	A	19970124		
NZ 327022	A	19990629	NZ 327022	A	19970124	199931	E
			WO 1997US300	A	19970124		
JP 2000503987	W	20000404	JP 1997526876	A	19970124	200027	E
			WO 1997US300	A	19970124		
AU 730642	B	20010308	AU 199715739	A	19970124	200119	E
AU 2001111100	A	20010510	AU 199715739	A	19970124	200130	NCE
			AU 2001111100	A	20010109		
EP 1193265	A2	20020403	EP 1997901952	A	19970124	200230	E
			EP 2001123289	A	19970124		
EP 880504	B1	20030402	EP 1997901952	A	19970124	200325	E
			WO 1997US300	A	19970124		
			EP 2001123289	A	19970124		
DE 69720428	E	20030508	DE 69720428	A	19970124	200338	E
			EP 1997901952	A	19970124		
			WO 1997US300	A	19970124		

Priority Applications (no., kind, date): US 2005183016 A 20050715; US 2003653399 A 20031999101493 A 19990602; WO 1997US300 A 19970124; WO 1995US9506 A 19950727; US 19960126

AU 76

ES 21

US 20

US 20

PH 11

Alerting Abstract WO A1

Sulphonylaryl-imidazole derivatives of formula (I) and their salts are new: in which R₁, R₂ = aminosulphonyl, alkylsulphonyl or haloalkylsulphonyl (AMS, ALS, or HALS), halo, cyano, hydroxylthio, alkoxyalkyl, alkoxy carbonyl, amino, alkylamino, arylamino, or nitro); provided that a substituent is an alkyl, haloalkyl, or hydroxyalkyl, 1–10C alkoxy or alkylthio, aralkyl, heterocycloalkyl, acyl, cycloalkylsulphonyl, haloalkylsulphonyl, arylsulphonyl, halogen, alkoxyalkyl, alkylcarbonyl, arylaminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-alkyl-N-arylaminoalkyl, carboxyalkyl, alkoxyalkylaminocarbonyl, alkylaminocarbonylalkyl, heteroarylalkoxyalkyl, heteroaryloxyalkyl, heteroaryloxyalkyl arylthio, aryloxy, aralkylthioalkyl, aralkoxyalkyl, aryl, or heterocyclo; R₄ = H, F, Cl, Br, I, or OCH₃; and R₅ = H, F, Cl, Br, I, or OCH₃. The claimed compounds are sulphonylaryl-imidazole derivatives of formula (V): R_{4'} = H, alkyl, or halo; and R_{5'} = H, F, Cl, Br, I, or OCH₃. The USE – (I) are cyclooxygenase (COX) inhibitors, with selectivity for COX-2 rather than COX-1. They are used as antipyretics in treatment of fever; and are non-steroidal antiinflammatory drugs (NSAIDs), for various forms of arthritis, lupus erythematosus, asthma, bronchitis, menstrual cramps, tendinitis, Crohn's disease, gastritis, irritable bowel, ulcerative colitis, prevention and treatment of carpal tunnel syndrome, aplastic anaemia, Hodgkin's disease, scleroderma, rheumatic fever, type I diabetes, neuromuscular disorders, sarcoidosis, nephrotic or Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity reactions, conjunctivitis, eye tissue injury, pulmonary inflammation from viral infections or cystic fibrosis, respiratory distress or endotoxic shock syndromes, atherosclerosis, or CNS damage from stroke, ischaemic heart disease, and hypertension. The ADVANTAGE – As selective COX-2 inhibitors, (I) do not cause the severe side effects, including those associated with corticosteroids.

Title Terms /Index Terms/Additional Words: NEW; SULPHONYL; ARYL; IMIDAZOLE; DERIVED; RELATED; DISORDER; ARTHRITIS; PAIN; HEADACHE; CAUSE; SIDE; EFFECT; ULCER

Class Codes

International Patent Classification

IPC	Class Level	Scope	Position	Status	Version Date
C07D-233/32; C07D-233/54			Main		"Version 7"
A61K-031/4164; A61K-031/4178; A61K-031/422; A61K-031/4439; A61K-031/4725; A61P-029/00; C07D- 233/90; C07D-401/04; C07D-401/12; C07D-403/04; C07D-405/04; C07D- 409/04; C07D-413/04; C07D-417/04			Secondary		"Version 7"
A61K-0031/415	A	I		R	20060101
A61K-0031/4178	A	I		R	20060101
A61K-0031/4439	A	I		R	20060101
A61K-0031/4709	A	I		R	20060101
A61K-0031/5377	A	I		R	20060101
A61P-0029/00	A	I		R	20060101
C07D-0233/32	A	I		R	20060101
C07D-0233/54	A	I		R	20060101
C07D-0233/90	A	I		R	20060101
C07D-0401/04	A	I		R	20060101
C07D-0401/12	A	I		R	20060101
C07D-0403/04	A	I		R	20060101
C07D-0405/04	A	I		R	20060101
C07D-0409/04	A	I		R	20060101
C07D-0413/02	A	I		R	20060101
C07D-0413/04	A	I		R	20060101
C07D-0417/04	A	I		R	20060101
C07D-0419/04	A	I		R	20060101
A61K-0031/415	C	I		R	20060101
A61K-0031/4164	C	I		R	20060101
A61K-0031/4427	C	I		R	20060101
A61K-0031/4709	C	I		R	20060101
A61K-0031/5375	C	I		R	20060101
A61P-0029/00	C	I		R	20060101
C07D-0233/00	C	I		R	20060101
C07D-0401/00	C	I		R	20060101
C07D-0403/00	C	I		R	20060101
C07D-0405/00	C	I		R	20060101

C07D-0409/00	C	I	R	20060101
C07D-0413/00	C	I	R	20060101
C07D-0417/00	C	I	R	20060101
C07D-0419/00	C	I	R	20060101

US Classification, Issued: 514397000, 514235500, 514326000, 514314000, 514341000,
514397000, 514400000, 546176000, 546210000, 546272700, 548311100 , 544139000,
514397000, 514399000, 514314000, 514341000, 514396000, 514398000, 514400000,
544139000, 546184000, 546334000, 548311400, 548315100 , 548315400, 548323500,
548325500

File Segment: CPI

DWPI Class: B02; B03

Manual Codes (CPI/A-N): B07-D09; B14-A02; B14-C01; B14-C03; B14-C04; B14-C09;
B14-E01; B14-F01E; B14-F02D; B14-F03; B14-G02A; B14-H01; B14-J01 ; B14-J01A3;
B14-K01; B14-K01A; B14-K01D; B14-N03; B14-N16; B14-N17A; B14-N17C; B14-S01;
B14-S04

Derwent WPI (Dialog® File 352): (c) 2006 The Thomson Corporation. All rights reserved.



© 2006 Dialog, a Thomson business



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		A1	(11) International Publication Number:	WO 97/27181
C07D 233/54, A61K 31/415, C07D 233/32, 233/90, 401/04, 403/04, 405/04, 409/04, 413/04, 417/04			(43) International Publication Date:	31 July 1997 (31.07.97)
(21) International Application Number:		PCT/US97/00300	855 Hinman Avenue, Evanston, IL 60202 (US). PARTIS, Richard, A. [US/US]; 2221 Noyes Street, Evanston, IL 60201 (US). KOSZYK, Francis, J. [US/US]; 11 Wildwood Drive South, Prospect Heights, IL 60070 (US). HUFF, Renee, M. [US/US]; 937 Lincoln Park, Park Ridge, IL 60068 (US).	
(22) International Filing Date:		24 January 1997 (24.01.97)	(74) Agents: WILLIAMS, Roger, A. et al.; G.D. Searle & Co., Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).	
(30) Priority Data:		US 08/592,167 26 January 1996 (26.01.96)	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(60) Parent Application or Grant		(63) Related by Continuation		
US Filed on		08/592,167 (CON) 26 January 1996 (26.01.96)		
(71) Applicant (for all designated States except US): G.D. SEARLE & CO. [US/US]; Corporate Patent Dept., P.O. Box 5110, Chicago, IL 60680-5110 (US).				
(72) Inventors; and		Published		
(75) Inventors/Applicants (for US only): KHANNA, Ish, K. [IN/US]; 149 Brandywine Court, Vernon Hills, IL 60061 (US). WEIER, Richard, M. [US/US]; 240 Hickory Court, Lake Bluff, IL 60044 (US). COLLINS, Paul, W. [US/US]; 1557 Hawthorne Place, Deerfield, IL 60015 (US). YU, Ui [CN/US]; 9065 Gross Point Road, GW, Skokie, IL 60077 (US). XU, Xiangdong [CN/US]; Apartment 715,		With international search report.		

(54) Title: HETEROCYCLO-SUBSTITUTED IMIDAZOLES FOR THE TREATMENT OF INFLAMMATION

(57) Abstract

A class of imidazolyl compounds is described for use in treating inflammation. Compounds of particular interest are defined by formula (V), wherein R³ is a radical selected from hydrido, alkyl, haloalkyl, aralkyl, heterocycloalkyl, heteroaralkyl, acyl, cyano, alkoxy, alkylthio, alkylthioalkyl, alkylsulfonyl, cycloalkylthio, cycloalkylthioalkyl, cycloalkylsulfonyl, cycloalkylsulfonylalkyl, haloalkylsulfonyl, arylsulfonyl, halo, hydroxyalkyl, alkoxyalkyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heterocyclocarbonyl, cyanoalkyl, aminoalkyl, alkylaminoalkyl, N-arylaminoalkyl, N-alkyl-N-arylaminoalkyl, carboxyalkyl, alkoxy- carbonylalkyl, alkoxy carbonyl, haloalkylcarbonyl, carboxyl, aminocarbonyl, alkylaminocarbonyl, alkylaminocarbonylalkyl, heteroarylalkoxyalkyl, heteroaryloxyalkyl, heteroarylthioalkyl, aralkoxy, aralkylthio, heteroaralkoxy, heteroaralkylthio, heteroarylalkylthioalkyl, heteroaryloxy, heteroarylthio, arylthioalkyl, aryloxyalkyl, arylthio, aryloxy, aralkylthioalkyl, aralkoxyalkyl, aryl and heteroaryl; wherein R⁴ is a radical selected from hydrido, alkyl and halo; and wherein R¹³ and R¹⁴ are independently selected from aryl and heterocyclo, wherein R¹³ and R¹⁴ are optionally substituted at a substitutable position with one or more radicals independently selected from alkylsulfonyl, aminosulfonyl, halo, alkylthio, alkyl, cyano, carboxyl, alkoxy carbonyl, haloalkyl, hydroxyl, alkoxy, hydroxyalkyl, alkoxyalkyl, haloalkoxy, amino, alkylamino, arylamino and nitro; provided at least one of R¹³ and R¹⁴ is aryl substituted with alkylsulfonyl or aminosulfonyl; or a pharmaceutically-acceptable salt thereof.

